Federal Lipitor Diabetes Litigation Moves Forward With Approval of Plaintiffs’ Fact Sheet, Bernstein Liebhard LLP Reports

The Firm is investigating Lipitor lawsuits on behalf of individuals who allegedly developed Type 2 diabetes due to their use of the statin medication.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
Free Case Review
Our Firm is evaluating a number of claims on behalf of individuals who allegedly developed diabetes due to their use of Lipitor. We are pleased with the progress in the federal litigation.

New York, New York (PRWEB) May 13, 2014

Hundreds of Lipitor lawsuits (http://www.thelipitorlawsuit.com/) filed on behalf of individuals who allegedly developed Type 2 diabetes due to their use of the statin medication continue to move forward in the U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. According to a Case Management Order dated May 2nd, the Court has approved a Plaintiffs’ Fact Sheet, which will allow the parties to exchange information pertaining to each individual Lipitor lawsuit filed in the proceeding. Plaintiffs who filed their claims prior to May 9, 2014 must submit a completed Fact Sheet to Pfizer, Inc. by June 2, 2014. All other plaintiffs must submit a completed form within 30 days of their filing. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)

“Our Firm is evaluating a number of claims on behalf of individuals who allegedly developed diabetes due to their use of Lipitor. We are pleased with the progress in the federal litigation,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Lipitor lawsuit reviews to individuals who took the statin and later developed Type 2 diabetes.

Lipitor Diabetes Allegations
According to court documents, Lipitor is a statin drug that is used to lower cholesterol levels. At least 464 Lipitor lawsuits have been filed in the District of South Carolina on behalf of individuals who allege that the drug increases the risk of developing Type 2 diabetes. Plaintiffs further allege that Pfizer was aware of the link between Lipitor and diabetes before modifying the drug’s label in February 2012 to reflect this risk, but concealed this information in order to protect sales of the medication. The complaints also maintain that the label modifications made in 2012 remain inadequate.

Court records indicate that the number of Lipitor diabetes claims has been increasing steadily since February 2012, when the U.S. Food & Drug Administration (FDA) ordered the manufacturers of statins to update their labels with information about the drugs’ potential association with Type 2 diabetes. The request followed the publication of a study in JAMA: Internal Medicine the previous month which suggested that post-menopausal women treated with statins faced an increased risk of developing new-onset Type 2 diabetes. *

Individuals who develop Type 2 diabetes allegedly due to Lipitor may be eligible to file their own Lipitor lawsuit. To learn more about the growing Lipitor diabetes litigation, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to obtain a free legal review.

*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993? As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.thelipitorlawsuit.com/
https://plus.google.com/115936073311125306742?rel=author